Continuing biopharma’s trend of upsized offerings in 2026, Latigo Biotherapeutics Inc. increased the number of shares and priced its IPO Aug. 7 on the high end of its proposed range, raising $345.6 million to advance a pipeline of non-opioid painkiller drugs targeting the Nav1.8 pathway.